On Wednesday, Travere earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.

When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the best-performing stocks often have an RS Rating of above 80 as they launch their biggest price moves.

Looking For Winning Stocks? Try This Simple Routine

Travere is now considered extended and out of buy range after clearing a 22.02 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

Earnings growth slowed last quarter from 0% to -77%. But revenue gains moved higher, from -1% to 13%.

The company earns the No. 134 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads and Alkermes are also among the group's highest-rated stocks.